The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
 
Riccardo Lencioni
Consulting or Advisory Role - Bayer; BTG; Eisai; Guerbet
Research Funding - BTG
 
Masatoshi Kudo
Honoraria - Ajinomoto; Bayer; Eisai; MSD
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; MSD; Taiho Pharmaceutical
Research Funding - Abbvie; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Otsuka; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Kwang-Hyub Han
Research Funding - Bayer; Bayer; Eisai; Kowa; Kowa
 
Kenji Ikeda
Honoraria - Dainippon Sumitomo Pharma; Eisai
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Fabio Piscaglia
Honoraria - Bayer; Bracco Diagnostics; Eisai
 
Guohong Han
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Eisai; Kyowa Hakko Kirin; NanoCarrier; Novartis; Shire
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxter; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Krzysztof Simon
Honoraria - Abbvie; Bristol-Myers Squibb; Gilead Sciences; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Gilead Sciences; MSD
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Gilead Sciences; MSD
Research Funding - Abbvie; Actelion; Allergan; Gilead Sciences; Intercept Pharmaceuticals; Pfizer
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences
 
Dmitry Komov
No Relationships to Disclose
 
Xuenong OuYang
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Clovis Oncology; Eisai
Consulting or Advisory Role - Baxalta (Inst); Bayer (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Karus Therapeutics (Inst); Otsuka (Inst); Roche/Genentech (Inst)
Research Funding - Basilea (Inst); Daiichi Sankyo (Inst); e-Therapeutics (Inst); Immunocare Therapies (Inst); Merck (Inst); TC Biopharm (Inst); Verastem (Inst); Vertex (Inst)
 
Max W. Sung
No Relationships to Disclose
 
Terri A. Binder
Employment - Eisai
 
Andrew Damon
Employment - Eisai
 
Silvija Kraljevic
Employment - Eisai
 
Min Ren
Employment - Eisai
 
Baek-Yeol Ryoo
No Relationships to Disclose